---
figid: PMC9634253__fonc-12-984525-g002
pmcid: PMC9634253
image_filename: fonc-12-984525-g002.jpg
figure_link: /pmc/articles/PMC9634253/figure/f2/
number: Figure 2
figure_title: ''
caption: 'Regulation of HIF-1α by hydroxylation, phosphorylation and acetylation.
  Activated regulatory pathways under normoxia: ①②; Activation of the following pathway
  is less associated with oxygen: ③④⑤⑥;Activated regulatory pathways under hypoxia:
  ⑦⑧⑨⑩⑪⑫⑬⑭⑮. PHD, prolyl hydroxylase; pVHL, Von Hippel-Lindau protein; ARD1, arrest
  defective-1; CBP/P300, cAMP response element binding protein (CREB)-binding protein
  and P300; ODDD, oxygen-dependent degradation domain; AMPK, adenosine 5’-monophosphate
  (AMP)-activated protein kinase; GSK3, glycogen synthase kinase-3; PLK3, polo-like
  kinase-3; MTA1, metastasis-associated protein 1; ATM, ataxia and telangiectasia
  mutated; p42/p44 MAPK, mitogen-activated protein kinase; CDK1, cyclin-dependent
  kinase-1; mTOR, mammalian target of rapamycin; STAT3, signal transducer and activator
  of transcription 3.'
article_title: Hypoxia-inducible factor 1-alpha is a driving mechanism linking chronic
  obstructive pulmonary disease to lung cancer.
citation: Yuan-rui Xu, et al. Front Oncol. 2022;12:984525.
year: '2022'

doi: 10.3389/fonc.2022.984525
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.

keywords:
- chronic obstructive pulmonary disease
- lung cancer
- non-small cell lung cancer
- hypoxia-inducible factor 1-alpha
- hypoxia-inducible factor 1

---
